A model for the future conduct of pharmacovigilance

被引：79

作者：

Waller, PC ^{[1
]}

Evans, SJW ^{[1
]}

机构：

[1] Med Control Agcy, Post Licensing Div, London, England

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2003年 / 12卷 / 01期

关键词：

pharmacovigilance; drug safety; strategy; model;

D O I：

10.1002/pds.773

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

A scientific model to support excellence in pharmacovigilance has been developed from first principles by brainstorming sessions and discussions with experts in the field. The model represents a long-term vision of how pharmacovigilance could be conducted in the future. So far it has been developed without any consideration of constraints such as resources or the need for legislative change. Although the vision is holistic, it would be possible to test and implement parts of the model in a piecemeal fashion. Copyright (C) 2002 John Wiley Sons, Ltd.

引用

页码：17 / 29

页数：13

共 22 条

[11] The role of the WHO programme on international drug monitoring in coordinating worldwide drug safety efforts [J].

Olsson, S .

DRUG SAFETY, 1998, 19 (01) :1-10

[12] What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects? [J].

Ozdemir, V ;

Shear, NH ;

Kalow, W .

DRUG SAFETY, 2001, 24 (02) :75-85

[13] Modeling methods for facilitating decisions in pharmaceutical policy and population therapeutics [J].

Patten, SB ;

Lee, RC .

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2002, 11 (02) :165-168

[14] BYAR,DAVID AS A TEACHER [J].

PIANTADOSI, S .

CONTROLLED CLINICAL TRIALS, 1995, 16 (04) :202-211

[15]

RAWLINS MD, 1995, J ROY COLL PHYS LOND, V29, P41

[16]

*UPPS MON CTR, 1998, EFF COMM PHARM ER RE

[17]

WALLER P, 2000, PHARMACOVIGILANCE PA, P26

[18]

Waller Patrick C., 1996, Pharmacoepidemiology and Drug Safety, V5, P363, DOI 10.1002/(SICI)1099-1557(199611)5:6<363::AID-PDS249>3.0.CO

[19]

2-7

[20]

Waller PC, 1999, PHARMACOEPIDEM DR S, V8, P535, DOI 10.1002/(SICI)1099-1557(199912)8:7<535::AID-PDS456>3.0.CO

← 1 2 3 →